1. Home
  2. ASTL vs CBIO Comparison

ASTL vs CBIO Comparison

Compare ASTL & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Algoma Steel Group Inc.

ASTL

Algoma Steel Group Inc.

HOLD

Current Price

$4.78

Market Cap

467.0M

Sector

Industrials

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$8.89

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTL
CBIO
Founded
1902
2003
Country
Canada
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
467.0M
389.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ASTL
CBIO
Price
$4.78
$8.89
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$27.17
AVG Volume (30 Days)
1.9M
236.4K
Earning Date
03-11-2026
02-18-2026
Dividend Yield
2.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,589,572,318.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$8.72
52 Week High
$8.28
$21.40

Technical Indicators

Market Signals
Indicator
ASTL
CBIO
Relative Strength Index (RSI) 55.24 29.40
Support Level $4.27 $8.72
Resistance Level $5.37 $9.69
Average True Range (ATR) 0.38 0.85
MACD 0.02 -0.10
Stochastic Oscillator 56.92 6.36

Price Performance

Historical Comparison
ASTL
CBIO

About ASTL Algoma Steel Group Inc.

Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: